Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
LANCET NEUROLOGY, cilt.16, sa.12, ss.976-986, 2017 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16 Sayı: 12
- Basım Tarihi: 2017
- Doi Numarası: 10.1016/s1474-4422(17)30369-1
- Dergi Adı: LANCET NEUROLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.976-986
- Karadeniz Teknik Üniversitesi Adresli: Evet
Özet
Background Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial.